Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Total Current Liabilities (2018 - 2026)

Exagen filings provide 9 years of Total Current Liabilities readings, the most recent being $12.6 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 10.23% to $12.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.6 million, a 10.23% decrease, with the full-year FY2025 number at $14.2 million, up 4.83% from a year prior.
  • Total Current Liabilities hit $12.6 million in Q1 2026 for Exagen, down from $14.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $14.2 million in Q4 2025 to a low of $8.6 million in Q2 2023.
  • Median Total Current Liabilities over the past 5 years was $10.3 million (2025), compared with a mean of $11.0 million.
  • Biggest five-year swings in Total Current Liabilities: dropped 22.01% in 2023 and later soared 59.34% in 2025.
  • Exagen's Total Current Liabilities stood at $9.6 million in 2022, then grew by 23.68% to $11.9 million in 2023, then grew by 13.48% to $13.5 million in 2024, then rose by 4.83% to $14.2 million in 2025, then decreased by 11.26% to $12.6 million in 2026.
  • The last three reported values for Total Current Liabilities were $12.6 million (Q1 2026), $14.2 million (Q4 2025), and $12.9 million (Q3 2025) per Business Quant data.